Navigation Links
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
Date:2/3/2009

y. The primary efficacy endpoint of the study was the increase in mean daily "ON" time ("ON" time without dyskinesia plus "ON" time with minor dyskinesia) during an 18-hour period as assessed by patients' recordings on diary cards.

Out of the 669 randomized patients, 89% of patients treated with safinamide completed the study (91% in the 50 mg dose group and 87% in the 100 mg dose group) compared to 89% in the placebo group. Over 90% of patients who completed the initial 24 weeks of treatment elected to enter a 78-week, placebo-controlled double-blind extension study, which is ongoing, to specifically assess the effect on dyskinesias as primary endpoint.

Secondary efficacy endpoints of this study were also met, including decrease in daily "OFF" time, decrease in mean "OFF" time following first morning dose of levodopa, mean change from baseline in the Unified Parkinson's Disease Rating Scale (UPDRS)(2) Section III (motor) score during "ON" time and mean change in Clinical Global Impression of severity of disease and change from baseline (CGI)(3). The incidence of dropouts, serious adverse events or clinically notable events among the three groups of the study were comparable.

Full study results after completion of ongoing analyses will be submitted for presentation at upcoming scientific meetings.

Merck Serono has exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson's disease, Alzheimer's disease and other therapeutic applications, as per the agreement signed with Newron in 2006.

About safinamide

Safinamide, an alpha-aminoamide derivative that is orally formulated, is currently being developed by Merck Serono and Newron as an add-on treatment for patients with Parkinson's disease. Safinamide is believed to have a novel dual mechanism of action based on the enhancement of the dopaminergic function (through reversible inhib
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
2. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
3. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
4. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
5. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
11. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the national association ... lawsuit in Iowa federal court ... law that restricts tools used by PBMs to lower ... The law—HF 2297—forces PBMs to overpay ... Maximum Allowable Cost (MAC) lists that keep generic drug ...
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com announces ... in its catalogue: Acute Heart Failure ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart ... Summary GlobalData,s clinical trial report, "Acute ... provides data on the Acute Heart Failure clinical ...
(Date:9/2/2014)... Spanje, September 2, 2014 ... AF Registry bij het ESC CONGRESS 2014 ... patiënten met risico op beroerte in de ... Gegevens van bijna 12.500 patiënten ingeschreven in ... Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief op ...
Breaking Medicine Technology:Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10
... Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide ... a conference call on Thursday, November 12, 2009, at ... operating performance for the first quarter ended September 30, ... and marketing activities. , Corgenix invites all those interested ...
... 3 On-Q-ity, a next-generation oncology diagnostics company ... that it has closed a $21 million series ... MDV-Mohr Davidow Ventures and included Bessemer Venture Partners, ... http://www.newscom.com/cgi-bin/prnh/20070702/AQM026LOGO ) , On-Q-ity is developing ...
Cached Medicine Technology:Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2
(Date:9/2/2014)... 2014 (HealthDay News) -- Complications are rare among ... a new study indicates. However, the researchers ... with a slightly higher risk for certain complications ... more than 18,000 breast cancer patients who had ... with breast reconstruction and were followed for 30 ...
(Date:9/2/2014)... can lay the groundwork for their own spread throughout ... send out tumor-welcoming signals, according to a new report ... 2 issue of Nature Communications , the researchers ... of so-called signaling molecules released by breast cancer cells. ... lungs and lymph nodes to produce proteins called CCL5 ...
(Date:9/2/2014)... Operators in the Community Services industry ... arranging care and counsel for those in need. In ... to derive $39.4 billion in revenue, which includes a ... the five years through 2014-15, the subdivision is forecast ... growth of 4.1% in 2014-15. , As the population ...
(Date:9/2/2014)... Melatonin supplements did not reduce delirium in seniors who ... Many older hospital patients experience the sudden, severe ... normal sleep-wake cycle. A lack of the hormone melatonin ... there has been little research into whether melatonin supplements ... patients, average age 84, who had hip fracture surgery. ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, ... outbreak continues to overwhelm health-care workers in three West ... the United Nations called on Tuesday for a concerted ... often-fatal virus. Dr. Thomas Frieden, director of the ... without a greater global commitment in resources -- both ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3
... depression resulting form multiple sclerosis had showed marked ... // The results of the investigation were reported ... Psychiatry. ,Although two-thirds of depressed patients prefer ... ever make a first appointment and nearly half ...
... the spread of gastrointestinal infections in the home. // ... families, which used the hand sanitizer in gel form, ... illness related to the gastrointestinal tract. ,Families ... Half the families were randomly assigned to receive hand ...
... high regard since the very old days and it continues ... recreation forms have been able to substitute mankind with another ... sudden death associated with exercise in young competitors. The benefits ... ,Recent medical research has reported that adolescents and ...
... elevate the role of fibres further by stating that ... plaque build-up in the arteries in postmenopausal women.// ... with a decreased risk of heart disease and death. ... fruit, and vegetables, and refined grain products on the ...
... said that the government would include Hepatitis B ... has been emerging as a "problem greater than ... Indian Council of Medical Research (ICMR)-World Health Organisation ... leptospirosis at the regional ICMR centre here, the ...
... Manoor Prakash Hande and his colleagues from National University ... risk of developing Chromosomal aberrations leading to cancer// in ... aimed at identifying biomarkers for easy detection and identification ... finding a link between complex chromosome aberrations and disease ...
Cached Medicine News:Health News:MS Patients Improve With Telephone Therapy 2Health News:Alcohol based sanitizer found to reduce illness in families 2Health News:Competitive Sports: Is the heart Sportive Enough? 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: